Lead Product(s) : Simvastatin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Simvastatin Tablets 80 mg of Dr. Reddy's Under Fasting Condition
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 22, 2010
Lead Product(s) : Simvastatin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Simvastatin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Simvastatin Tablets, 80 mg of Dr. Reddy's Under Fed Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 22, 2010
Lead Product(s) : Simvastatin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Simvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SLCO1B1 (simvastatin) is a medication in the statin family of drugs, commonly prescribed to lower cholesterol to help reduce the risk of heart attack and stroke.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 27, 2022
Lead Product(s) : Simvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aspirin,Ramipril,Simvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : CNIC
Deal Size : Inapplicable
Deal Type : Inapplicable
The Polypill Reduces Cardiovascular Mortality By 33% In Patients Treated After Myocardial Infarction
Details : The polypill includes three drugs (aspirin, an ACE inhibitor, and a statin), is effective at preventing secondary adverse cardiovascular events in people who have previously had a heart attack.
Product Name : Polypill
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 26, 2022
Lead Product(s) : Aspirin,Ramipril,Simvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : CNIC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Simvastatin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2022
Lead Product(s) : Simvastatin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Simvastatin
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Immunogenics
Deal Size : Inapplicable
Deal Type : Inapplicable
Simvastatin Metabolism as a Test for CD Activity (IRB 15-007568]
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 06, 2017
Lead Product(s) : Simvastatin
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Immunogenics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Simvastatin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Celerion
Deal Size : Inapplicable
Deal Type : Inapplicable
Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 07, 2015
Lead Product(s) : Simvastatin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Celerion
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Simvastatin
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Children's Healthcare of Atlanta
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2015
Lead Product(s) : Simvastatin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Children's Healthcare of Atlanta
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Simvastatin
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 22, 2014
Lead Product(s) : Simvastatin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Simvastatin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Michael J. Gill Mental Health Clinic | Massachusetts Mental Health Center | Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital | The Edinburg Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 11, 2014
Lead Product(s) : Simvastatin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Michael J. Gill Mental Health Clinic | Massachusetts Mental Health Center | Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital | The Edinburg Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
